Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Completed Phase 2 Interventional

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

NCT06429722
View directory record Official record
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 16, 2026, 11:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Pregnant and Postpartum Women With and Without Mood Disorders

NCT03615794
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Postpartum Depression, Postpartum Psychosis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

NCT00200902
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI)
Drug · Other · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 3 Interventional

Study of Adolescence and Depression

NCT00523081
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Active control
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
12 Years to 18 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 4 Interventional Results available

Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome

NCT01035073
View directory record Official record
Conditions
Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
Interventions
Duloxetine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 16, 2026, 11:38 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness

NCT03814356
View directory record Official record
Conditions
Brain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered, Anoxic Brain Injury
Interventions
Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 16, 2026, 11:38 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Palliative Care Needs of Children With Rare Diseases and Their Families

NCT06938542
View directory record Official record
Conditions
Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
Interventions
Family Centered pediatric palliative care for family caregivers of children with rare diseases.
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Months to 99 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 16, 2026, 11:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Regulation of Emotions in People With Depression and Anhedonia

NCT00059579
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Nicotine Dependence and Acute Depression

NCT00186446
View directory record Official record
Conditions
Major Depressive Disorder, Nicotine Dependence
Interventions
bupropion and smoking cessation behavioral intervention
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

Pilot Decentralized Trial

NCT05419869
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-100 PO Tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Coral Gables, Florida • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Targeting IL-17A for Treatment-Resistant Depression

NCT04979910
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ixekizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

NCT02285504
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

NCT00384033
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
638 participants
Timeline
2006 – 2007
U.S. locations
22
States / cities
Beverly Hills, California • Burbank, California • Encino, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Positive Feedback vs. No-Feedback Games for Behavioral Change

NCT06025838
View directory record Official record
Conditions
Major Depressive Disorder, Low Mood
Interventions
positive feedback
Behavioral
Lead sponsor
Bard College
Other
Eligibility
18 Years to 34 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Annandale-on-Hudson, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 16, 2026, 11:38 PM EDT
Active, not recruiting Not applicable Interventional

Getting Out of the House: Using Behavioral Activation to Increase Community Participation

NCT06336616
View directory record Official record
Conditions
Major Depressive Disorder, Schizo Affective Disorder, Schizophrenia, Bipolar Disorder
Interventions
Behavior Activation
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 4 Interventional Results available

A Study of L-DOPA for Depression and Slowing in Older Adults

NCT02744391
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Decreased Processing Speed, Decreased Gait Speed
Interventions
Levodopa
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Antidepressant therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 16, 2026, 11:38 PM EDT
Completed No phase listed Observational

Implementation of Harmonized Depression Outcome Measures in a Primary Care Registry and a Mental Health Registry

NCT04235725
View directory record Official record
Conditions
Major Depression, Dysthymia
Interventions
Harmonized Depression Outcome Measures
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Not applicable Interventional

McLean and Genomind Prospective Study

NCT03113890
View directory record Official record
Conditions
Major Depressive Disorder, PTSD
Interventions
Phlebotomy - Folate, Cheek Swab, Self-report surveys
Genetic · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 16, 2026, 11:38 PM EDT
Recruiting Phase 2 Interventional

JAK Signaling in Depression

NCT07003997
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 11:38 PM EDT
Not listed Not applicable Interventional

Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression

NCT01473615
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Chronic Pain
Interventions
Mindfulness Based Cognitive Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 16, 2026, 11:38 PM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

NCT00321490
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 16, 2026, 11:38 PM EDT
Terminated Phase 2 Interventional Results available

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

NCT01103180
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 16, 2026, 11:38 PM EDT